Oncimmune
Oncimmune Holdings PLC is a UK-listed biotech that develops and commercializes its proprietary EarlyCDT platform for early cancer detection via oncology biomarker diagnostics and liquid biopsy, serving healthcare providers and oncology research institutions.
- Company typePublic
- Founded2006
- HeadquartersNottingham, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Oncimmune does
Oncimmune Holdings PLC is an AIM-listed UK biotech headquartered in Leeds (with original operations noted in Nottingham) that develops and commercializes its proprietary EarlyCDT platform technology for early cancer detection. The company's core proposition centers on oncology biomarker diagnostics, including liquid-biopsy-based approaches, serving healthcare providers, hospital oncology departments, and cancer research institutions that require non-invasive methods for early-stage cancer identification and personalized treatment planning.
The technology stack revolves around the EarlyCDT platform, which leverages autoantibody-based biomarker measurement — an immunological approach aimed at detecting cancer signatures before clinical symptoms emerge. The 2019 acquisition of Protagen broadened the company's footprint into adjacent immune-profiling and personalized cancer diagnostics, extending the offering beyond the original EarlyCDT product line.
Commercially, Oncimmune operates with 51–100 employees and sells diagnostic products and biomarker services to the healthcare and oncology sector. Specific product SKUs, unit pricing, and customer logos are not disclosed in the available sources; distribution is presumed to flow through healthcare procurement and direct sales to medical institutions consistent with AIM-listed diagnostics peers. The company is led by CEO Martin Gouldstone alongside founder John Robertson, CFO Matthew Hall, CCO Matthew Luttrell, and Chief Business Officer Cameron Barnard. In October 2024 the company completed a recapitalization of approximately £2.45 million (placing, subscription, and retail offer) with concurrent debt-to-equity conversion to support recent contract wins and ongoing operations.
Oncimmune firmographics
Firmographics- Name
- Oncimmune
- Legal name
- Oncimmune Holdings PLC
- Website
- https://oncimmune.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Oncimmune Holdings PLC is a UK-listed biotech that develops and commercializes its proprietary EarlyCDT platform for early cancer detection via oncology biomarker diagnostics and liquid biopsy, serving healthcare providers and oncology research institutions.
- Ownership category
- akta.pro rank
Oncimmune industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
Keywords
Where Oncimmune is headquartered
LocationHeadquarters
- HQ city
- Nottingham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Oncimmune business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Oncimmune product offering
Product offeringCore offering
Oncimmune develops and commercializes its EarlyCDT platform technology for early cancer detection. The company operates in the oncology biomarkers and cancer diagnostics space, with a focus on liquid biopsy approaches and biomarker-based tests that support personalized oncology therapy development and improved patient outcomes through earlier diagnosis.
Product overview
Oncimmune Holdings PLC is a Leeds-based biotech company operating in the oncology diagnostics and precision medicine space. The company's primary focus appears to be in cancer biomarkers and liquid biopsy technologies for early cancer detection, as evidenced by industry market reports. However, the specific named products, modules, or service offerings are not detailed in the available source material.
Differentiator
Problem solved
Functional benefit
Products and services
- EarlyCDT Platform
Companies that use Oncimmune
Customer profileSegments1 record
Ideal customer profiles1 record
Oncimmune technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Oncimmune partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights3 records
Oncimmune competitors and assessment
Company assessmentDirect peers
- Guardant Health: Guardant Health is a leading liquid biopsy company offering blood-based cancer diagnostics across screening, therapy selection, and MRD. Like Oncimmune, it operates in oncology diagnostics (tumor profiling, MRD, liquid biopsy), making it the most direct large-cap peer.
- Natera: Natera develops blood-based molecular diagnostics for oncology and reproductive health, including the Signatera MRD assay. Directly comparable to Oncimmune's EarlyCDT platform in the liquid biopsy / oncology diagnostics space.
- NeoGenomics: NeoGenomics operates a specialized oncology-focused clinical laboratory providing biomarker, molecular, and esoteric cancer testing. Directly comparable to Oncimmune in serving oncology providers with diagnostic testing services.
- VolitionRx: VolitionRx is a small-cap biotech developing blood-based diagnostic tests for cancer using nucleosomics. Closely analogous to Oncimmune as an early-stage, blood-based cancer detection company.
- Biodesix: Biodesix develops blood-based proteomic and genomic diagnostic tests for lung disease and cancer. Directly comparable to Oncimmune in delivering blood-based oncology biomarker diagnostics.
- Personalis: Personalis is a cancer genomics company focused on immune profiling and MRD monitoring via its NeXT Personal platform. Comparable to Oncimmune in oncology molecular diagnostics and immune-profiling capabilities (especially relevant given Protagen acquisition).
Broad incumbents
- Exact Sciences: Exact Sciences is a larger, established cancer diagnostics company best known for Cologuard and Oncotype DX. Comparable to Oncimmune as a broad-incumbent commercial player in cancer screening and oncology diagnostics with established US payer coverage.
- Foundation Medicine: Foundation Medicine provides comprehensive genomic profiling services for solid tumors, used to guide therapy selection. Comparable to Oncimmune as a molecular diagnostics provider in the oncology/tumor profiling category, though at much larger scale (now part of Roche).
- Sysmex Inostics: Sysmex Inostics is the liquid biopsy subsidiary of Sysmex, offering blood-based tumor profiling and ultra-sensitive oncology testing. Comparable to Oncimmune as a liquid biopsy / oncology diagnostics player, though backed by the larger Sysmex corporate parent.
Emerging players
- Freenome: Freenome is a privately held molecular diagnostics company developing blood-based multi-cancer early detection tests. Overlaps with Oncimmune's EarlyCDT early-cancer-detection focus as an emerging, VC-backed entrant in the same category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Oncimmune social profiles
Digital presenceOncimmune financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oncimmune leadership team
Management profileNumber of profiles
Profiles5 records
Oncimmune funding detail
Funding detailFunding overview
Funding rounds6 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oncimmune M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oncimmune
What does Oncimmune do?
Oncimmune develops and commercializes its EarlyCDT platform technology for early cancer detection. The company operates in the oncology biomarkers and cancer diagnostics space, with a focus on liquid biopsy approaches and biomarker-based tests that support personalized oncology therapy development and improved patient outcomes through earlier diagnosis.
Is Oncimmune a public or private company?
Oncimmune is a public company. It is classified as public and is currently operating.
When was Oncimmune founded?
Oncimmune was founded in 2006. It employs 51 to 100 people.
Where is Oncimmune based?
Oncimmune is headquartered in Nottingham, United Kingdom, in the Europe region.
Who are Oncimmune's main competitors?
Direct peers on record are Guardant Health, Natera, NeoGenomics, VolitionRx, Biodesix and Personalis. Broad incumbents are Exact Sciences, Foundation Medicine and Sysmex Inostics. Freenome is listed as an emerging player.
Does Oncimmune have an API?
No public API is recorded for Oncimmune.
What industry is Oncimmune in?
Oncimmune's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 325413 and its SIC code is 2835.